135 related articles for article (PubMed ID: 2117107)
1. Interleukin-2 therapy for human cancer.
van Hoesel QG
Lung; 1990; 168 Suppl():1069-74. PubMed ID: 2117107
[TBL] [Abstract][Full Text] [Related]
2. An explanation of the variable clinical response to interleukin 2 and LAK cells.
Parmiani G
Immunol Today; 1990 Apr; 11(4):113-5. PubMed ID: 2187466
[TBL] [Abstract][Full Text] [Related]
3. [Interleukin 2: immunologic background and clinical use in tumor therapy].
Dummer R; Welters H; Keilholz U; Tilgen W; Burg G
Hautarzt; 1990 Feb; 41(2):53-5. PubMed ID: 2180854
[TBL] [Abstract][Full Text] [Related]
4. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
Kimoto Y
Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
[TBL] [Abstract][Full Text] [Related]
5. Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms.
Atzpodien J; Kirchner H
Klin Wochenschr; 1990 Jan; 68(1):1-11. PubMed ID: 2407894
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
Schultz KR; Klarnet JP; Peace DJ; Cheever MA; Badger CC; Bernstein ID; Greenberg PD
Cancer Res; 1990 Sep; 50(17):5421-5. PubMed ID: 2386946
[TBL] [Abstract][Full Text] [Related]
7. [Adoptive immunotherapy in malignant tumors].
KiselevskiÄ MV
Vestn Ross Akad Med Nauk; 2003; (1):40-4. PubMed ID: 12608084
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
Kimoto Y; Taguchi T
Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor.
Tjota A; Zhang YQ; Piedmonte MR; Lee CL
J Urol; 1991 Jul; 146(1):177-83. PubMed ID: 2056587
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
[TBL] [Abstract][Full Text] [Related]
13. [The influence of anticancer agents at various stages to induce LAK cell on its cytotoxicity and cell yield. Examination in vitro].
Baba M
Nihon Ika Daigaku Zasshi; 1990 Dec; 57(6):531-40. PubMed ID: 2286645
[TBL] [Abstract][Full Text] [Related]
14. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
Yoshida S; Tanaka R; Takai N; Ono K
Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631
[TBL] [Abstract][Full Text] [Related]
15. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
16. LAK cell therapy--clinical studies and future potential.
Marshall GD; Schwartzberg LS; Tauer KW; Lee P; Holbert JM; West WH
Prog Clin Biol Res; 1990; 337():555-8. PubMed ID: 2191342
[No Abstract] [Full Text] [Related]
17. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model.
Marincola FM; Da Pozzo LF; Drucker BJ; Holder WD
Surgery; 1990 Nov; 108(5):919-29. PubMed ID: 2237773
[TBL] [Abstract][Full Text] [Related]
18. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
[TBL] [Abstract][Full Text] [Related]
19. [Adoptive immunotherapy with LAK cell and IL-2 against primary lung cancer].
Kimura H; Yamaguchi Y
Nihon Geka Gakkai Zasshi; 1989 Sep; 90(9):1459-62. PubMed ID: 2586439
[TBL] [Abstract][Full Text] [Related]
20. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases.
Keilholz U; Scheibenbogen C; Brado M; Georgi P; Maclachlan D; Brado B; Hunstein W
Eur J Cancer; 1994; 30A(1):103-5. PubMed ID: 8142149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]